Faculty: Matthew Zirwas, MD For the afternoon product theater, Dr. Matthew Zirwas explored Dupixent for the treatment of atopic dermatitis (AD). He began his presentation with the statement “what you think of atopic dermatitis is wrong”. Dr. Zirwas reports childhood onset is not a defining criterion for the diagnosis of atopic dermatitis. He relayed the …
Featuring Adam Friedman, MD, FAAD Dr. Adam Friedman returned for the afternoon product theater to discuss atopic dermatitis (AD) and treatment with Dupixent. Dupixent is a treatment for moderate to severe atopic dermatitis in patients 12 years of age or older whose disease is not adequately controlled with topical prescription therapies. Dr. Friedman reports “atopic …
On day two of the 16th Annual Fall Conference, Cynthia Trickett, MPAS, PA-C, DFAAPA shared her clinical insights regarding the treatment of atopic dermatitis (AD) in her lecture on Dupixent. AD is estimated to affect 3.2% of adults in the US and around 1.6 million with moderate to severe AD remain uncontrolled despite treatment. Ms. …